CN109528775A - 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 - Google Patents
脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 Download PDFInfo
- Publication number
- CN109528775A CN109528775A CN201710865410.6A CN201710865410A CN109528775A CN 109528775 A CN109528775 A CN 109528775A CN 201710865410 A CN201710865410 A CN 201710865410A CN 109528775 A CN109528775 A CN 109528775A
- Authority
- CN
- China
- Prior art keywords
- bacteroides fragilis
- pharmaceutical composition
- preventing tumor
- inactivation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000606124 Bacteroides fragilis Species 0.000 title claims abstract description 110
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 230000036541 health Effects 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 235000013373 food additive Nutrition 0.000 claims abstract description 9
- 239000002778 food additive Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 241000894006 Bacteria Species 0.000 claims description 27
- 230000002779 inactivation Effects 0.000 claims description 17
- 239000012228 culture supernatant Substances 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 15
- 239000006166 lysate Substances 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 230000006798 recombination Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 230000009466 transformation Effects 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 9
- 241000606125 Bacteroides Species 0.000 claims description 6
- 241000682973 Quasibacillus Species 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 235000012241 calcium silicate Nutrition 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 5
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- JHXCINJSAAFBDH-UHFFFAOYSA-N [Ca].O[Si](O)(O)O Chemical compound [Ca].O[Si](O)(O)O JHXCINJSAAFBDH-UHFFFAOYSA-N 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012826 global research Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (11)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710865410.6A CN109528775A (zh) | 2017-09-22 | 2017-09-22 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
PCT/CN2017/103940 WO2019056404A1 (zh) | 2017-09-22 | 2017-09-28 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
US16/648,774 US20200384040A1 (en) | 2017-09-22 | 2017-09-28 | Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710865410.6A CN109528775A (zh) | 2017-09-22 | 2017-09-22 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109528775A true CN109528775A (zh) | 2019-03-29 |
Family
ID=65811006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710865410.6A Pending CN109528775A (zh) | 2017-09-22 | 2017-09-22 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20200384040A1 (zh) |
CN (1) | CN109528775A (zh) |
WO (1) | WO2019056404A1 (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109200063A (zh) * | 2017-06-29 | 2019-01-15 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用 |
CN109793761A (zh) * | 2017-11-17 | 2019-05-24 | 中山大学 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
CN111920793A (zh) * | 2019-04-25 | 2020-11-13 | 瑞微(深圳)生物科技有限公司 | 泛酸在制备用于治疗和/或预防肿瘤的组合物中的应用 |
CN114306616A (zh) * | 2022-01-12 | 2022-04-12 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
CN114306615A (zh) * | 2022-01-12 | 2022-04-12 | 广州知易生物科技有限公司 | 脆弱拟杆菌荚膜多糖a与免疫检查点抑制剂的新应用 |
CN114404598A (zh) * | 2022-01-12 | 2022-04-29 | 广州知易生物科技有限公司 | 脆弱拟杆菌荚膜多糖a联合pd-1抑制剂在制备治疗皮肤肿瘤的药物中的应用 |
CN114344325B (zh) * | 2022-01-12 | 2023-07-14 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于防治生殖泌尿系统肿瘤的药物中的应用 |
WO2023134201A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌与免疫检查点抑制剂联用在治疗消化系统肿瘤中的应用 |
WO2023134208A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌与pd-1或pd-l1抗体联合用药治疗生殖泌尿系统癌症的应用 |
WO2023134212A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用 |
WO2023134195A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌联合免疫检查点抑制剂在治疗皮肤肿瘤中的应用 |
WO2023134203A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于治疗呼吸系统肿瘤药物中的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110496140B (zh) * | 2018-05-18 | 2022-05-31 | 瑞微(深圳)生物科技有限公司 | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 |
CN115960738A (zh) * | 2021-10-12 | 2023-04-14 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌灭活菌粉及其制备方法 |
CN114344340B (zh) * | 2022-01-12 | 2023-07-25 | 广州知易生物科技有限公司 | 脆弱拟杆菌与pd-1及pd-l1抗体联合用药治疗呼吸系统肿瘤中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099750A1 (en) * | 2004-04-16 | 2005-10-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Vaccination against malignant melanoma using bcg and/or vaccinia |
CN103142656A (zh) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备防治结肠癌组合物中的应用 |
CN105434476A (zh) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用 |
CN106399141A (zh) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1029857C (zh) * | 1990-05-03 | 1995-09-27 | 张季阶 | 拟杆菌微生态制剂的制备方法 |
CN101125151A (zh) * | 2006-08-16 | 2008-02-20 | 大连森佰澳科技有限公司 | 类杆菌信号分子微生态制剂及其制备方法 |
CA2836413A1 (en) * | 2010-06-01 | 2011-12-08 | Moore Research Enterprises Llc | Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof |
US11571446B2 (en) * | 2016-11-18 | 2023-02-07 | Sanford Bumham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
CN110496140B (zh) * | 2018-05-18 | 2022-05-31 | 瑞微(深圳)生物科技有限公司 | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 |
-
2017
- 2017-09-22 CN CN201710865410.6A patent/CN109528775A/zh active Pending
- 2017-09-28 US US16/648,774 patent/US20200384040A1/en not_active Abandoned
- 2017-09-28 WO PCT/CN2017/103940 patent/WO2019056404A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099750A1 (en) * | 2004-04-16 | 2005-10-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Vaccination against malignant melanoma using bcg and/or vaccinia |
CN103142656A (zh) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备防治结肠癌组合物中的应用 |
CN106399141A (zh) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌及其应用 |
CN105434476A (zh) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用 |
Non-Patent Citations (2)
Title |
---|
MARIE VÉTIZOU等: "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", 《SCIENCE》 * |
靳雅荣等: "肠道菌群干预肿瘤负性免疫调控机制的研究进展", 《中国肿瘤生物治疗杂志》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109200063A (zh) * | 2017-06-29 | 2019-01-15 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用 |
CN109793761A (zh) * | 2017-11-17 | 2019-05-24 | 中山大学 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
CN109793761B (zh) * | 2017-11-17 | 2021-03-05 | 瑞微(深圳)生物科技有限公司 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
CN111920793A (zh) * | 2019-04-25 | 2020-11-13 | 瑞微(深圳)生物科技有限公司 | 泛酸在制备用于治疗和/或预防肿瘤的组合物中的应用 |
WO2023134209A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
CN114306615A (zh) * | 2022-01-12 | 2022-04-12 | 广州知易生物科技有限公司 | 脆弱拟杆菌荚膜多糖a与免疫检查点抑制剂的新应用 |
CN114404598A (zh) * | 2022-01-12 | 2022-04-29 | 广州知易生物科技有限公司 | 脆弱拟杆菌荚膜多糖a联合pd-1抑制剂在制备治疗皮肤肿瘤的药物中的应用 |
CN114344325B (zh) * | 2022-01-12 | 2023-07-14 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于防治生殖泌尿系统肿瘤的药物中的应用 |
CN114306616A (zh) * | 2022-01-12 | 2022-04-12 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
WO2023134206A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于防治生殖泌尿系统肿瘤的药物中的应用 |
WO2023134201A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌与免疫检查点抑制剂联用在治疗消化系统肿瘤中的应用 |
WO2023134208A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌与pd-1或pd-l1抗体联合用药治疗生殖泌尿系统癌症的应用 |
WO2023134212A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用 |
WO2023134195A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌联合免疫检查点抑制剂在治疗皮肤肿瘤中的应用 |
WO2023134203A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于治疗呼吸系统肿瘤药物中的应用 |
CN114306615B (zh) * | 2022-01-12 | 2023-11-17 | 广州知易生物科技有限公司 | 脆弱拟杆菌荚膜多糖a与免疫检查点抑制剂的新应用 |
Also Published As
Publication number | Publication date |
---|---|
US20200384040A1 (en) | 2020-12-10 |
WO2019056404A1 (zh) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109528775A (zh) | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 | |
CN110496140B (zh) | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 | |
CN109793761B (zh) | 一种用于增强t细胞免疫功能的组合物及其制备方法 | |
CN110638838B (zh) | 阿克曼粘细菌或普氏菌在制备用于增强抗肿瘤免疫功能的药物中的应用 | |
CN111004757A (zh) | 一种罗伊氏乳杆菌、微生物菌剂及食物制品 | |
CN101306020A (zh) | 酪酸梭菌在制备预防和治疗肠癌药物组合物中的应用 | |
CN115414390A (zh) | 具有改善肠道微生态性能和增强肿瘤免疫检查点抑制剂治疗效果的益生菌复合制剂及应用 | |
CN111450124B (zh) | 阿克曼粘菌或普氏菌在增加肿瘤微环境γδT细胞积累并增强抗肿瘤免疫功能药物中的应用 | |
CN102920771B (zh) | 一种用于治疗家禽球虫病的药物 | |
Yu et al. | Suppressing tumor progression of in vitro prostate cancer cells by emitted psychosomatic power through Zen meditation | |
KR101168789B1 (ko) | 살모넬라 균주를 이용한 항암치료용 nk 세포의 활성화 방법 | |
CN103202861A (zh) | 酪酸梭菌、双歧杆菌二联活菌制剂与抗癌药物组合在制备治疗肠癌药物中的应用 | |
CN106668076A (zh) | 一种抗癌药酒及其制备方法与应用 | |
CN102232957B (zh) | 3-乙酰氧基-8,24-羊毛甾二烯-21-酸在制备预防、治疗肝癌或乳腺癌药物中的用途 | |
CN105412155A (zh) | 拟康氏木霉胞外多糖治疗和预防结肠癌的应用、及其联用化疗药物治疗结肠癌的应用 | |
CN106994123A (zh) | 吲哚美辛在制备预防和治疗癌症药物方面的应用 | |
Mokriani et al. | Comparison of anti-tumor properties of the cell walls of Saccharomyces cerevisiae and Saccharomyces boulardi probiotics, individually and in combination with iron nanoparticles on K562 cancer cell line | |
Wainson et al. | Facilitation of rehabilitation of the patients undergoing tumor radiotherapy by increasing therapeutic interval in the damage of malignant and normal tissues with Halophilic Archaebacteria homogenate | |
Bhatnagar et al. | Opening avenues in marine probiotics: Present and future | |
CN106667907A (zh) | 一种广谱抗肿瘤复合制剂 | |
CN113813259A (zh) | 奥替尼啶双盐酸盐在制备抗肿瘤药物中的应用 | |
Liu et al. | Therapeutic Applications of Functional Nanomaterials for Prostatitis. Front. Pharmacol. 12: 685465. doi: 10.3389/fphar. 2021.685465 | |
Downey | Probiotic-Phage Blend Fights Digestive Problems and Boosts Immune Defenses. | |
Albookarami | Investigating the role of probiotics in coping with cancer and health in society | |
Ali | Mechanisms underlying anticancer effect of lactobacilli (lab 12 and labpc) against human colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190910 Address after: 518054 Donghua Garden, Nanshan Street, Nanshan District, Shenzhen City, Guangdong Province, 810 Applicant after: SHENZHEN YUEYAO LIFE TECHNOLOGY Co.,Ltd. Address before: 510275 Xingang West Road, Guangdong, China, No. 135, No. Applicant before: Sun Yat-sen University |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200727 Address after: 3009 venture capital building, No.9 Tengfei Road, huanggekeng community, Longcheng street, Longgang District, Shenzhen City, Guangdong Province Applicant after: Ruiwei (Shenzhen) Biotechnology Co.,Ltd. Address before: 518054 Donghua Garden, Nanshan Street, Nanshan District, Shenzhen City, Guangdong Province, 810 Applicant before: SHENZHEN YUEYAO LIFE TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |
|
RJ01 | Rejection of invention patent application after publication |